SkinCure Oncology company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Loan | Alive

Total Raised


Last Raised

$3.5M | 2 yrs ago

About SkinCure Oncology

SkinCure Oncology is a support system trusted by dermatologists for superficial radiation therapy (SRT) skin cancer treatment.

SkinCure Oncology Headquarter Location

745 McClintock Dr Suite 330

Hinsdale, Illinois, 60527,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SkinCure Oncology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SkinCure Oncology is included in 3 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Medical Devices

8,079 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

Latest SkinCure Oncology News

10:00 EDT SkinCure Oncology Marks Skin Cancer Awareness Month, Encouraging Patients to Have a "Voice and a Choice" in Their Trea...

May 3, 2022

News provided by Share this article Share this article BURR RIDGE, Ill., May 3, 2022 /PRNewswire/ -- May is Skin Cancer Awareness Month, and SkinCure Oncology  has launched a campaign to encourage people with common skin cancers to learn about effective, evidence-based treatment options and choose the course that's best for them. The company that provides a comprehensive model for the delivery of Image-Guided Superficial Radiotherapy (Image-Guided SRT), the most advanced non-surgical technology for the treatment of basal and squamous cell carcinoma, believes that educated patients will take a more active role with their doctors in making critical health care decisions. Some 3.3 million Americans are diagnosed with nonmelanoma skin cancer each year, with about 2,000 deaths resulting. While physicians traditionally opted to perform Mohs surgery on most patients with these cancers, Image-Guided SRT is frequently preferred today. With Mohs, the surgeon uses a scalpel to trim away suspicious tissue until microscopic examination of the tissue shows that all the cancer is removed. But with Image-Guided SRT, which has a 99.3 percent effectiveness rate, there is no surgery. Instead, low-level radiation, similar to x-rays, is directed at the cancer over the course of a series of short office visits. Ultrasound imaging enables more precise targeting of the radiation and allows patients to actually see their cancer shrink and disappear. Unlike Mohs surgery, there is no cutting, bleeding or surgical scarring. "While surgery is indicated in some cases, it may have become the default prescription for these types of cancer even though less invasive treatment options exist," said Daniel Ladd, D.O., FAOCD, FAAD, and medical director of SkinCure Oncology. "If we truly want an informed patient, one who takes an active role in their health, we must do a better job of giving them access to the knowledge that will get them there, assuring that they have a voice and a choice in their treatment." Anchored by an appeal for patients and their families to "Get skINFORMED" about treatment options, the SkinCure Oncology campaign includes literature, billboards, social media and a patient education website, . Dr. Ladd noted that simple precautions can reduce the risk of getting skin cancer, such as using high-SPF sunscreen, wearing protective clothing, minimizing sun exposure, and avoiding all indoor tanning devices. "Given the relative ease of avoiding skin cancer and newer patient-friendly treatment options, everyone should follow the golden rule – be sun smart and get regular medical check-ups," he concluded. About SkinCure Oncology SkinCure Oncology is the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiotherapy (Image-Guided SRT), the most advanced non-surgical technology for the treatment of common skin cancers. The company partners with quality-focused dermatologists and Mohs surgeons to bring cancer center-level radiotherapy treatment to physician offices. To date, SkinCure Oncology is working with more than 200 dermatology practice locations across the country, and more than 40,000 patients have been treated with Image-Guided SRT over the last five years. Learn more about the company at , and visit for helpful consumer and patient information. Media Contact:

SkinCure Oncology Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SkinCure Oncology Rank

  • Where is SkinCure Oncology's headquarters?

    SkinCure Oncology's headquarters is located at 745 McClintock Dr, Hinsdale.

  • What is SkinCure Oncology's latest funding round?

    SkinCure Oncology's latest funding round is Loan.

  • How much did SkinCure Oncology raise?

    SkinCure Oncology raised a total of $36.97M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.